Virtual Fireside Chat with Dean Alex Triantis and Dean's Advisory Board Member Abe Abraham, MD, MBA '15

Alex Triantis joined the Johns Hopkins Carey Business School in 2019 as its third dean. During his tenure, he has led the revision or launch of a large suite of graduate degree programs, including Full-time, Accelerated, Flexible, and Executive MBA programs, seven MS programs offered in both full-time and online formats, and over a dozen dual degree programs. Carey’s reputation for innovative interdisciplinary research and impactful outreach has been further enhanced through its unique positioning in the Business of Health and in AI, its eight new centers of excellence, and its high-profile events featuring corporate and government leaders in Baltimore and at the Johns Hopkins University Bloomberg Center in Washington, D.C.

Before joining Carey Business School, Triantis served as dean of the Robert H. Smith School of Business at the University of Maryland from 2013 to 2019, and chair of the Finance Department from 2006 to 2011. He previously served on the faculty at the University of Wisconsin and was a visiting scholar at MIT’s Sloan School of Management. Triantis received his PhD from Stanford University and his BASc and MEng degrees from the University of Toronto.

An expert in the areas of corporate financial strategy and valuation, Triantis has published articles in numerous prestigious academic journals, served on several journal editorial boards, and has consulted and led training for many multinational corporations. Businessweek named Triantis an Outstanding Professor at the University of Wisconsin and the University of Maryland, and he is a two-time recipient of Maryland Smith’s top teaching award for faculty.

Triantis served on the board of AACSB, the global association of business schools, from 2019-2025, and as board chair in 2023-2024.

Abe Abraham is an executive medical leader with a career spanning biopharma development, medical affairs, and entrepreneurial innovation. He oversaw Phase I-IV trials and FDA/EMA submissions, including first-in-human programs recognized for excellence in design and regulatory quality. At Genentech, he orchestrated agile transformation in US Medical Affairs and shaped medical strategy across immunology portfolios, including Actemra, Rituxan, Obinutuzumab, and Fenebrutinib. As Medical Lead at Neurocrine Biosciences, he led the medical launch of the first FDA-approved therapy for congenital adrenal hyperplasia. Abe is a two-time founder, currently serving as Chief Medical Officer and Chief Operating Officer of a stealth venture at the intersection of AI and biotechnology. He earned his MBA at Johns Hopkins, completed postdoctoral clinical research training at the University of Chicago, and remains active as a mentor and advisor, committed to fostering diversity and inclusion across biotechnology.